IHH Healthcare - DBS Research 2016-07-04: Recreating the magic in Hong Kong

SGinvestors.io

IHH HEALTHCARE BERHAD Q0F.SI 

IHH Healthcare - Recreating the magic in Hong Kong

• Gleneagles HK leads IHH’s ‘Growth 2.0’
• Medium-term growth from new hospitals
• Limited downside risks
• Upgrade to BUY, TP of RM7.60

Gleneagles Hong Kong leads IHH’s ‘Growth 2.0’. 

• The long awaited Gleneagles HK, targeted to open by Jan 2017 leads IHH into its next phase of growth. 
• We are positive on the prospects of Gleneagles HK and believe the positive impact could be double that of Mount Elizabeth Novena (Mt E Novena), given that Gleneagles HK is more than double the size of operational beds in Mt E Novena (500 beds in Gleneagles HK versus 180 operational beds in Mt E Novena).

Medium-term growth from new hospitals, China and India. 

• Management targets to add c.1k (includes Gleneagles HK) new beds by end-2017, with the opening of two other hospitals in 2017. 
• Subsequently, IHH plans to further expand its footprints in China (ParkwayHealth Shanghai Hospital by 2020) and in India (via its newly acquired Global and Continental Hospitals). 
• However, we believe these new hospitals would start contributing significantly post-2022 (when they stabilise).

Limited downside risks. 

• While we believe that earnings growth could moderate in the near term due to 
  1. start-up/pre- operating costs of new hospitals, and 
  2. macro-economic headwinds, 
  we believe downside risks are limited as the healthcare sector remains resilient amid market uncertainties. 
• In addition, foreign shareholdings have fallen to IPO levels at 21%. 
• We believe any share price weakness offers a good entry opportunity for medium- to long-term growth prospects.

Valuation:

Upgrade to BUY, TP of RM7.60. 

• We upgrade our rating to BUY (from HOLD) with a revised TP of RM7.60/S$2.51 (from RM6.33/S$2.09) by including the DCF valuation of Gleneagles HK and raising the EV/EBITDA multiples of Malaysia and Turkey as the operations in these markets mature. 
• IHH trades at FY17F EV/EBITDA of 22x, close to the historical average of 21x, in line with regional peers.

Key Risks to Our View:

1. Economic slowdown; 
2. lower-than-expected performance, especially in new markets; 
3. higher-than-expected start-up and pre-operating costs; and 
4. government policy changes.

Rachel Lih Rui Tan DBS Vickers | Andy Sim CFA DBS Vickers | http://www.dbsvickers.com/ 2016-07-04

DBS Vickers SGX Stock Analyst Report BUY Upgrade HOLD 2.51 Up 2.09